Program
Zocilurtatug Pelitecan
Also written as “ZL-1310” and “ZL-1310 in combination with Atezolizumab or Durvalumab”.
Its studies are mostly in Small Cell Lung Carcinoma, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Zai Lab | 44 open or running | phase 3since Oct 8, 2025 | Dec 7, 2023 | May 30, 2027phase 1 · NCT06179069 |
| Amgen | 11 open or running | phase 1since Apr 9, 2026 | Apr 9, 2026 | May 21, 2028phase 1 · NCT07531095 |
| Boehringer Ingelheim | 11 open or running | phase 2since Jul 13, 2026 | Jul 13, 2026 | Apr 26, 2030phase 2 · NCT07707895 |
Also a collaborator on its studies: Zai Lab (US).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 7, 2023First study: phase 1 study in SCLCNew to Zai LabZai Lab · NCT06179069 · 339 planned · United States, China, Israel and more
- Feb 24, 2025Phase 2 study in Solid TumorsZai Lab · NCT06885281 · 166 planned · United States, China
- Oct 8, 2025Phase 3 study in Small Cell Lung CarcinomaZai Lab · NCT07218146 · 480 planned · United States, Austria, Belgium and more
- Apr 9, 2026Amgen’s first study: phase 1 study in Small Cell Lung CarcinomaNew to AmgenAmgen · NCT07531095 · 160 planned · United States, Australia, Belgium and more
- Jul 13, 2026Boehringer Ingelheim’s first study: phase 2 study in Small Cell Lung CarcinomaNew to Boehringer IngelheimBoehringer Ingelheim · NCT07707895 · 60 planned · United States, Australia, Belgium and more
- Aug 24, 2026Phase 3 study in Small Cell Lung CarcinomaZai Lab · NCT07796100 · 530 planned
Ahead
- May 30, 2027Primary completion: phase 1 study in SCLCZai Lab · NCT06179069
- Aug 2027Primary completion: phase 2 study in Solid TumorsZai Lab · NCT06885281
- May 21, 2028Primary completion: phase 1 study in Small Cell Lung CarcinomaAmgen · NCT07531095
- Jun 30, 2028Primary completion: phase 3 study in Small Cell Lung CarcinomaZai Lab · NCT07218146
TargetBeta
“An antibody-drug conjugate (ADC) composed of zocilurtatug, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) and ”NCIt, by rule
Other programs on DLL3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tarlatamabrule | Amgen | phase 3 | 13 |
| Alveltamigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 11 |
| obrixtamig | Boehringer Ingelheim | phase 3 | 11 |
| Anti-DLL3 Antibody-drug Conjugate BL-M14D1 | Sichuan Biokin Pharmaceutical | phase 3 | 4 |
| gocatamig | Merck | phase 3 | 4 |
| Autologous Anti-DLL3 CAR-T Cells DJI136 | Novartis | phase 2 | 2 |
| Anti-DLL3 Antibody-drug Conjugate IDE849 | ideaya-biosciences | phase 2 | 2 |
| SHR-7787 | Jiangsu HengRui Medicine | phase 2 | 1 |
| Anti-DLL3 Antibody-drug Conjugate FZ-AD005rule | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical | phase 1 | 2 |
| clesitamig | Hoffmann-La Roche | phase 1 | 2 |
| Actinium Ac 225-ABD147rule | abdera-therapeutics-inc | phase 1 | 1 |
| Indium In 111-ETN029 | Novartis | phase 1 | 1 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07796100Small Cell Lung Carcinoma | 3 | Not yet recruiting | Zai Lab | Jun 30, 2030 | 530 |
| NCT07707895Small Cell Lung Carcinoma · United States, Australia, Belgium and more | 2 | Recruiting | Boehringer Ingelheim | Apr 26, 2030 | 60 |
| NCT07531095Small Cell Lung Carcinoma · United States, Australia, Belgium and more | 1 | Recruiting | Amgen | May 21, 2028 | 160 |
| NCT07218146Small Cell Lung Carcinoma · United States, Austria, Belgium and more | 3 | Recruiting | Zai Lab | Jun 30, 2028 | 480 |
| NCT06885281Solid Tumors · United States, China | 2 | Recruiting | Zai Lab | Aug 2027 | 166 |
| NCT06179069SCLC · United States, China, Israel and more | 1 | Recruiting | Zai Lab | May 30, 2027 | 339 |
How it is read
Names in the registry
- “ZL-1310”, 5 entries
- “ZL-1310 in combination with Atezolizumab or Durvalumab”, 1 entry
Codes read as this program: ZL1310.
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.